Sanofi completes acquisition of Vicebio

赛诺菲完成对Vicebio的收购

Paris, December 4, 2025

巴黎，2025年12月4日

. Sanofi announces the completion of its

. 赛诺菲宣布已完成其

acquisition of Vicebio Ltd (“Vicebio”)

收购Vicebio有限公司（“Vicebio”）

.

。

This acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology.

这项收购带来了一个针对呼吸道合胞病毒（RSV）和人类偏肺病毒（HMPV）的早期联合疫苗候选者，这两种均为呼吸道病毒，并通过Vicebio的“分子夹”技术扩展了疫苗设计和开发的能力。

The acquired vaccine candidate complements Sanofi’s position in respiratory vaccines. It enables Sanofi to offer increased physician and patient choice in RSV and HMPV by adding a non-mRNA vaccine to its pipeline.

该获得的疫苗候选产品补充了赛诺菲在呼吸道疫苗领域的地位。通过在其产品线中增加一种非mRNA疫苗，它使赛诺菲能够提供更多的RSV和HMPV医生和患者选择。

About Sanofi

关于赛诺菲

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

赛诺菲是一家以研发为驱动、以人工智能为助力的生物制药公司，致力于改善人们的生活并实现引人注目的增长。我们凭借对免疫系统的深刻理解，发明能够治疗和保护全球数百万人的药物和疫苗，同时拥有一个创新的研发管线，有望使数百万人进一步受益。我们的团队秉持一个使命：追逐科学的奇迹以改善人们的生活；这激励我们通过应对当今最紧迫的医疗、环境和社会挑战，推动进步并为我们服务的人群和社区带来积极影响。

.

。

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

赛诺菲在EURONEXT（巴黎泛欧交易所）上市，股票代码为SAN；同时在NASDAQ（纳斯达克）上市，股票代码为SNY。

Media Relations

媒体关系

Sandrine Guendoul

桑德琳·根杜尔

| +33 6 25 09 14 25 |

| +33 6 25 09 14 25 |

sandrine.guendoul@sanofi.com

桑德琳·根杜尔@赛诺菲.com

Evan Berland

埃文·贝兰德

| +1 215 432 0234 |

| +1 215 432 0234 |

evan.berland@sanofi.com

埃文·伯兰@赛诺菲.com

Léo Le Bourhis

里奥·勒布尔希斯

| +33 6 75 06 43 81 |

| +33 6 75 06 43 81 |

leo.lebourhis@sanofi.com

leo.lebourhis@sanofi.com

Victor Rouault

维克多·鲁奥

| +33 6 70 93 71 40 |

| +33 6 70 93 71 40 |

victor.rouault@sanofi.com

victor.rouault@sanofi.com

Timothy Gilbert

蒂莫西·吉尔伯特

| +1 516 521 2929 |

| +1 516 521 2929 |

timothy.gilbert@sanofi.com

timothy.gilbert@sanofi.com

Léa Ubaldi

莉娅·乌巴尔迪

| +33 6 30 19 66 46 |

| +33 6 30 19 66 46 |

lea.ubaldi@sanofi.com

lea.ubaldi@sanofi.com

Investor Relations

投资者关系

Thomas Kudsk Larsen

托马斯·库德斯克·拉森

| +44 7545 513 693 |

| +44 7545 513 693 |

thomas.larsen@sanofi.com

托马斯.拉森@赛诺菲.com

Alizé Kaisserian

阿利泽·凯塞里安

| +33 6 47 04 12 11 |

| +33 6 47 04 12 11 |

alize.kaisserian@sanofi.com

alize.kaisserian@sanofi.com

Felix Lauscher

费利克斯·劳舍尔

| +1 908 612 7239 |

| +1 908 612 7239 |

felix.lauscher@sanofi.com

felix.lauscher@sanofi.com

Keita Browne

凯塔·布朗

| +1 781 249 1766 |

| +1 781 249 1766 |

keita.browne@sanofi.com

keita.browne@sanofi.com

Nathalie Pham

娜塔莉·范

| +33 7 85 93 30 17 |

| +33 7 85 93 30 17 |

nathalie.pham@sanofi.com

娜塔莉·法姆@赛诺菲.com

Tarik Elgoutni

塔里克·埃尔古特尼

| +1 617 710 3587 |

| +1 617 710 3587 |

tarik.elgoutni@sanofi.com

塔里克·埃尔古特尼@赛诺菲.com

Thibaud Châtelet

蒂博·沙泰莱

| +33 6 80 80 89 90 |

| +33 6 80 80 89 90 |

thibaud.chatelet@sanofi.com

thibaud.chatelet@sanofi.com

Yun Li

李云

| +33 6 84 00 90 72 |

| +33 6 84 00 90 72 |

yun.li3@sanofi.com

yun.li3@sanofi.com

Sanofi Forward-Looking Statements

赛诺菲前瞻性声明

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance.

本新闻稿包含1995年《私人证券诉讼改革法案》（经修订）所定义的前瞻性陈述。前瞻性陈述并非历史事实。这些陈述包括预测、估计及其基本假设，有关未来财务结果、事件、运营、服务、产品开发和潜力的计划、目标、意图和期望的陈述，以及有关未来业绩的陈述。

Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

前瞻性声明通常可以通过“预期”、“预计”、“相信”、“打算”、“估计”、“计划”等词语以及类似的表述加以识别。尽管赛诺菲的管理层认为这些前瞻性声明中反映的预期是合理的，但投资者应注意，前瞻性信息和声明受到各种风险和不确定性的约束，其中许多难以预测且通常超出赛诺菲的控制范围，可能导致实际结果和发展与前瞻性信息和声明中表达、暗示或预测的内容存在重大差异。

These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and com.

这些风险和不确定性包括但不限于研发、未来临床数据及分析（包括上市后）中固有的不确定性，监管机构（如FDA或EMA）关于是否以及何时批准任何可能为这些候选产品提交的药物、器械或生物制品申请的决定，以及他们关于标签和其他可能影响这些候选产品的可用性或商业潜力的事宜的决定，候选产品即便获得批准也可能无法取得商业成功的事实，未来的批准和商业化进程等。

Attachment

附件

Press_Release

新闻发布

Share

分享